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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at
4q35.2 from 11-100 copies to 1-10 copies. The extent to which D4Z4 contraction at 4q35.2 affects overall 4q35.2 chromatin
organization remains unclear. Because DNA replication timing is highly predictive of long-range chromatin interactions, we
generated genome-wide replication-timing profiles for FSHD and control myogenic precursor cells. We compared non-
immortalized myoblasts from four FSHD patients and three control individuals to each other and to a variety of other
human cell types. This study also represents the first genome-wide comparison of replication timing profiles in non-
immortalized human cell cultures. Myoblasts from both control and FSHD individuals all shared a myoblast-specific
replication profile. In contrast, male and female individuals were readily distinguished by monoallelic differences in
replication timing at DXZ4 and other regions across the X chromosome affected by X inactivation. We conclude that
replication timing is a robust cell-type specific feature that is unaffected by FSHD-related D4Z4 contraction.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an auto-
somal dominant genetic disorder characterized by progressive
muscle weakness and wasting that typically initiates in the face,
shoulder-girdle and upper arm. Together with clinical character-
istics of the disease, transcription-profiling studies support a model
for FSHD involving impaired muscle regeneration [1,2]. FSHD is
linked to contraction of the D4Z4 tandem repeat at subtelomeric
4q35.2 (OMIM 606009). Usually 11-100 copies of the 3.3 kb
repeat unit are non-pathogenic while 1-10 copies correlate with
onset of FSHD in 95% of patients [3]. Another D4Z4
macrosatellite array highly homologous to that of 4q35.2 is
present at 10q26.3, yet D4Z4 contractions at 10q26 are almost
never pathogenic [4]. The current paradigm suggests that
pathogenicity of D4Z4 at 4q35.2 is linked to FSHD through a
D4Z4 gene encoding Double Homeobox Protein 4 (DUX4)
[5,4,6]; however, its pathogenic mechanism is unclear. The open
reading frame encoding DUX4 protein within each D4Z4 repeat
unit lacks a consensus signal for polyadenylation [7]. A single
nucleotide polymorphism distal to the last D4Z4 repeat is found in
all FSHD patients and stabilizes DUX4 transcripts by providing a
polyadenylation signal and thereby creating a toxic gain-of-
function mutation [4,8]. However, although forced DUX4
expression inhibits myogenesis and decreases Myogenic Differentiation
1 (MYOD1) transcription [9,10], only about one in a thousand
FSHD myoblasts has detectable DUX4 expression and expression
in FSHD myotubes is not much stronger [6,2]. In addition, the
polyadenylation signal polymorphism, which stabilizes the DUX4-
encoding transcript is prevalent in the general population and,
therefore, disease status is still strongly linked to D4Z4 contraction
per se. We recently proposed a model in which frequent, but
transient, expression of DUX4 at a pre-myoblast stage drives the
muscular dystrophy phenotype of FSHD patients [2].
While DUX4 involvement in FSHD pathogenesis clearly
requires at least one D4Z4 repeat, the mechanism by which
D4Z4 contraction beyond a threshold array length usually leads to
DUX4 expression remains uncertain. It has been proposed that the
repetitive nature of D4Z4 arrays creates a heterochromatin
environment at 4q35.2 that maintains low regional gene
expression under normal conditions [11,12], and that the loss of
this heterochromatic region is pathogenic. Several studies
identified hallmarks of heterochromatin in normal individuals at
the D4Z4 region and at a similar macrosatellite repeat on the
human X chromosome called DXZ4 [13-16]. Although evidence
of chromatin relaxation has been observed in D4Z4 at 4q35.2 in
FSHD patients with contracted D4Z4 arrays, rare cases of FSHD
patients without contraction of the D4Z4 array at 4q35.2 also
display chromatin relaxation [14–16]. Moreover, epigenetic marks
indicative of heterochromatin do not appear to spread from full
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have not detected any gradient of altered gene expression in the
4q35.2 region [1,2,19]. As an alternative hypothesis, it has been
proposed that long-range chromatin interactions distant from the
4q35.2 D4Z4 locus may occur in the muscle lineage as a result of
pathogenic contraction of the D4Z4 array [15,17,18,20–22].
The temporal order of replication of chromosomal segments is
reflective of cell-type-specific chromatin organization and changes
coordinately with the differentiation state during development [23–
29]. We recently demonstrated that genome-wide maps of long-
range chromatin interactions generated by high-resolution chro-
matin conformation capture methods (Hi-C maps) [30], can be
almost precisely mirrored by genome-wide profiles of replication
timing [27]. Since replication-timing profiles are much easier to
generate than Hi-C maps, we examined whether replication-timing
maps could provide evidence for the existence of novel long-range
chromatin interactions in myoblasts from FSHD versus control
individuals. Although the replication timing in the D4Z4 vicinity at
4q35.2 is unperturbed in FSHD myoblasts [31], it remained
possible that array contraction could alter chromosome folding at
long distances from the repeat. Indeed, artificially seeded telomeres
were shown to replicate later when adjacent to a single D4Z4 repeat
than when adjacent to multiple repeats [32]. Additionally, since
even closely related cell types can be clearly distinguished by
comparing genome-wide replication timing profiles [26], the
hypothesis that muscle differentiation is altered in FSHD [1,2]
suggests that at least some replication timing profile differences
might exist between control and FSHD myoblasts. We found that
replication timing profiles from control myoblasts were indistin-
guishable from those obtained from FSHD myoblasts. The
maintenance of replication timing profiles among human myoblast
cultures derived from different healthy muscle biopsies or from a
disease background underscores the robustness of the replication
timing program within a given cell type. In addition, the lack of
replication timing differences genome-wide suggest that D4Z4
chromatin relaxation at 4q35 does not cause irregular long-range
chromatin interactions in FSHD myogenic precursors.
Results and Discussion
FSHD and control myoblast cultures
In studies of primary myoblasts, it is critical to determine what
percentage of the cells are actually myoblasts because contami-
nating fibroblast-like cells can have a growth advantage if optimal
conditions are not maintained for the myoblasts. We showed that
.85% of the cells in aliquots from all batches of FSHD and
control myoblasts used in this study were myoblasts by
immunostaining with desmin, a muscle-specific marker not
expressed in fibroblasts. In addition, we verified that these batches
of cells could efficiently differentiate to myotubes (multinucleated,
desmin-immunopositive, and heavy chain myosin-immunoposi-
tive). Similarly, Winokur et al. and Barro et al. [33,34] showed that
FSHD and control myoblasts form multinucleated myotubes with
equal efficiency.
Figure 1. Method for generation of genome-wide replication profiles of primary myoblasts. Step 1 illustrates BrdU labeling of actively
dividing cells for 2 hours, followed by fixation and FACS sorting by DNA content into early and late S phase fractions. In step 2, BrdU-labeled DNA
from each fraction was isolated by immunoprecipitation. Step 3 involved differential-labeling and co-hybridization to a whole-genome human CGH
microarray. For the final step, arrays were scanned and the extracted log2(early/late) raw data was Loess normalized (represented by gray data points)
and then smoothed (dark blue curve) [35]. Shown is a profile of approximately 60 Mb of chromosome 10 for patient CM1.
doi:10.1371/journal.pone.0027413.g001
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contracted D4Z4 repeat array at 4q35 are associated with FSHD,
we assayed, by previously described methods [4], six control and
six FSHD myoblast samples, including three samples used in the
present study [2]. We found, as previously reported [6], that the
average levels of these transcripts were extremely low in FSHD
myoblasts, that this transcript was undetectable in control
myoblasts, and that only some of the FSHD myoblast cell strains
had detectable transcripts [2]. The control samples CM4 and
CM5, used in the present study, were negative and FM7, used in
this study, was positive for these transcripts under RT-PCR
conditions previously reported (400 ng of cDNA per assay and
qRT-PCR conditions [4]). Because only about 1/1000 FSHD
myoblasts produce detectable full-length DUX4 transcripts [6], the
presence or absence of these transcripts should not detectably
influence the behavior of a culture of FSHD myoblasts.
Nonetheless, well-characterized FSHD myoblast cultures have
an oxidative stress hypersensitivity phenotype [33,34] and, as we
have recently shown, a highly significantly dysregulated expression
profile [2]. Therefore, we tested these cells from biopsies of
moderately affected muscle of FSHD patients for irregularities in
DNA replication timing compared to normal-control myoblasts.
FSHD and control myoblasts share a common
genome-wide replication timing profile
To determine the extent to which the FSHD disease
background affects the replication timing program, we profiled
replication timing in FSHD and control primary myoblasts
genome-wide. Generation of genome-wide replication timing
profiles is illustrated in Figure 1. First, nascent DNA in
asynchronously growing myoblasts was labeled with 5-bromo-2-
deoxyuridine (BrdU). Labeled myoblasts were then sorted into
early and late S-phase fractions based on DNA content using flow
cytometry, and BrdU-labeled DNA was purified by immunopre-
cipitation. Purified DNA fractions were differentially labeled and
co-hybridized to a Comparative Genomic Hybridization (CGH)
microarray with 2.5 kb median probe spacing across the entire
human genome. Hybridization data was then Loess normalized
and smoothed to provide a genome-wide profile with relative
replication timing values for each probe position [35]. Similar
Pearson’s correlations resulted when genome-wide myoblast
replication timing profiles from three control individuals were
compared to each other and to myoblast profiles from four FSHD
individuals (Figure 2A). Biological replicates from different cell
Figure 2. Similarity between FSHD and control myoblast genome-wide replication timing profiles and other cell types. (A) Genome-
wide Pearson’s correlations between individual control (begins with ‘‘C’’) and FSHD (begins with ‘‘F’’) primary myoblast timing profiles are displayed.
Gray indicates control to control or FSHD to FSHD comparison. One FSHD dataset (FM7) had a low signal to noise ratio and deviates somewhat from
other datasets, but was still included for comparison. (B) Genome-wide Pearson’s correlations between averaged control and FSHD myoblasts as well
as other human cell types are displayed. Gray indicates control to FSHD myoblast comparison.
doi:10.1371/journal.pone.0027413.g002
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show high correlation to each other [27] and are consistent with
profiles created at higher probe density [23] or by deep sequencing
of similarly prepared BrdU-labeled nascent strands [27]. Thus, the
high genome-wide correlations indicate the replication-timing
program is largely maintained in the FSHD myoblasts profiled.
D4Z4 repeat contraction does not affect 4q35 or 10q26
replication timing
Three groups found no detectable difference in the intranuclear
localization of unique probes in the vicinity of D4Z4 at 4q35.2 in
FSHD versus control myoblasts [12,31,36]. However, there are
several reports of evidence for changes in chromatin organization at
4q35.2 within the 200-kb region distal to D4Z4 that contains mostly
segmental duplications [21,22]. To identify any localized changes
proximal to the subtelomeric D4Z4 arrays, we more closely
examined FSHD-linked 4q35 and highly homologous 10q26
subtelomeres, which contain almost identical D4Z4 repeat units.
All the FSHD myoblast samples profiled came from patients with
documented contraction of a 4q35 D4Z4 array. The control samples
were obtained from unaffected first-degree relatives of FSHD
patients over the age of 25, and most patients exhibit symptoms in
their teenage years [3]. Therefore, because FSHD is a dominant
genetic disease, the controls are expected to contain 4q35 D4Z4
arrays of normal size as was verified for one of the control samples
(CM1). We found that replication timing was indistinguishable in
FSHD myoblasts relative to control myoblasts at both 4q35
(Figure 3A) and 10q26 (Figure 4A). Due to the repetitive nature of
D4Z4anditslocationinaregionofsegmentalduplication,theclosest
unique probes on our microarrays were about 100 kb proximal to
4q35.2 D4Z4 and 45 kb proximal to 10q26.3. Nonetheless,
replication forks move at approximately 2 kb per minute, so that
at least 200 kb of DNA is labeled during the 2-hour BrdU labeling
period [35]. Hence, any replication timing changes in the D4Z4
repeat should be readily detected 45 kb away. Moreover, a previous
study using fluorescence in situ hybridization concluded that D4Z4
repeat contraction has no local effect on replication timing [31].
Replication timing profiles reflect efficient myoblast
differentiation in FSHD
Because FSHD was proposed to be a disease involving muscle
differentiation [1], we compared our genome-wide myoblast profiles
Figure 3. D4Z4 contraction and FSHD disease background do not affect 4q35 replication timing. (A) Primary human myoblast
replication timing profiles are shown for 3 control (gray) individuals and 4 FSHD (red) patients across the proximal region to 4q35. One FSHD dataset
(FM7) had a low signal to noise ratio and deviates somewhat from other datasets, but was still included for comparison. (B) Replication timing profiles
for many different human cell types are shown across the proximal region to 4q35. Boxed in red is the region of human chromosome 4
corresponding to 4q35. Microarray probe positions are indicated along the X-axis by short black vertical lines. Genes are indicated by black dots, for
those whose name is given, or gray dots, for those with too high a density to add a label. DUX4 transcripts derived from 4q35.2 D4Z4 map between
hg18 chromosome 4 coordinates 191,229,361 and 191,247,457 (UCSC Genome Browser, http://genome.ucsc.edu/).
doi:10.1371/journal.pone.0027413.g003
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program is extensively re-organized during differentiation of all cell
types examined to date [23–29], and developmental changes in
replication timing reflect concomitant changes in large-scale
chromatin organization [20,37]. We found that averaged profiles
for FSHD and control myoblasts were significantly more similar to
each other genome-wide than would be expected for profiles from
different cell types (Figure 2B). Close examination of both 4q35 and
10q26 reveals overall myoblast-specific replication timing profiles
withseveralindividualregionsthat arereplicatedatdifferenttimesin
different cell types (Figures 3B and 4B). SLC25A4, for example, is an
FSHD-candidate gene on 4q35.1 that replicates early in some cell
types (including myoblasts) but replicates in mid or late S phase in
other cell types. Further, the 4q35.2 cluster of genes ZFP42,
TRIML1, and TRIML2, and the surrounding gene desert replicated
early in embryonic stem cells (ESCs) and late in all other cell types
consistent with the association of these genes with early embryo-
genesis (Figure 3B). FAT1 replicated earlier during S phase in
myoblasts and fibroblasts, which strongly transcribe this gene [2].
Additionally, a second gene desert proximal to FRG1 and distal to
TRIML1 contains a region that replicates early specifically in
fibroblasts, while FRG1 itself replicates in mid to late S phase in all
cell types examined. Interestingly, the FRG1-proximal gene desert
contains a DNaseI hypersensitive site found in fibroblasts and
observed preferentially in FSHD versus control myoblasts [38].
However, replication-timing profiles were indistinguishable between
FSHD and control myoblasts throughout 4q35 and 10q26.
Moreover, our FSHD myoblast cell strains, which are grown under
optimal conditions and contain .85% desmin-positive cells, grew
and differentiated just as efficiently as control myoblasts, gave
normal-looking myotubes, and had no deficiency in MYOD1
transcription although several hundred genes were dysregulated in
FSHD vs. control myoblasts [2]. Retention of myogenesis together
with preservation of a wild-type myoblast replication timing profile
suggests that the large-scale myogenesis-specific chromatin reorga-
nization events are normal in FSHD myoblasts.
No significant replication timing differences exist
genome-wide in myoblasts from FSHD vs. control
individuals
Next, to locate any regions with consistent replication timing
changes in FSHD profiles, we employed a statistical method that
Figure 4. D4Z4 contraction and FSHD disease background do not affect 10q26 replication timing. (A) Primary human myoblast
replication timing profiles are shown for 3 control (gray) individuals and 4 FSHD (red) patients across the proximal region to 10q26. One FSHD dataset
(FM7) had a low signal to noise ratio and deviates somewhat from other datasets, but was still included for comparison. (B) Replication timing profiles
for many different human cell types are shown across the proximal region to 10q26. Boxed in red is the region of human chromosome 10
corresponding to 10q26. Microarray probe positions are indicated along the X-axis by short black vertical lines. Genes are indicated by black dots, for
those whose name is given, or gray dots, for those with too high a density to add a label. DUX4 transcripts derived from 10q26.3 D4Z4 map between
hg18 chromosome 10 coordinates 135,330,358 and 135,338,574 (UCSC Genome Browser, http://genome.ucsc.edu/).
doi:10.1371/journal.pone.0027413.g004
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both minimized between groups of designated replicates and
maximized between designated test groups [39]. This statistical
algorithm identified very few small differences between all control
versus all FSHD replicate profiles. Figure 5 compares the
replication profiles from normal and FSHD myoblasts across
8 Mb surrounding each of the three most significant differences
detected by our algorithm. Even these selected regions were highly
similar in all replicates, indicating that the FSHD disease
background had no detectable effect on genome-wide replication
timing in myoblasts.
Individual myoblast timing profiles are indistinguishable
except across regions affected by X chromosome
inactivation
To determine whether any replication timing differences could
be detected between genetically polymorphic individuals and to
determine the sensitivity of detection of modest average replication
timing differences, we examined replication timing of the X and Y
chromosomes in individual myoblast profiles. Although no
autosomal regions exhibited differences, female profiles were
easily distinguished from male samples, both by the absence of
hybridization to Y-chromosome specific probes on the microarray,
and also by tendency toward later average replication timing
across the X chromosome (Figure 5C). This is in accord with these
regions replicating later on one of the two female X chromosomes
after X inactivation [40–42]. These results confirm that the
replication-timing program is conserved across polymorphic
human individuals and also demonstrates that significant mono-
allelic replication-timing differences can be detected by our
genome-wide profiling method. This is consistent with our
previous demonstration that the method used here can readily
detect replication-timing differences between female mouse cells
containing two active X chromosomes versus one active and one
inactive X chromosome (Xi) [26]. Intriguingly, all the replication-
timing differences involved switches to later replication except in
the region containing the DXZ4 repeat, which was earlier on the
Xi (Figure 6). Early replication of DXZ4 on the Xi is consistent
with the array’s euchromatic structure and CCCTC binding factor
(CTCF) association specifically on the Xi [43–46].
Myoblast replication timing is most similar to fibroblast
replication timing
The genome-wide profiles from this study also revealed that
human myoblast replication timing profiles most closely resemble
fibroblast timing profiles amongst the cell types compared
Figure 5. Regions of greatest statistical difference between control and FSHD myoblast replication timing profiles. (A, B, C) Primary
human myoblast replication timing profiles are shown for 3 control (gray) individuals and 4 FSHD (red) patients across the top three 200 kb regions
(on chromosomes 5, 11, and X respectively) of greatest difference as identified using a distance-maximizing statistical method [39]. Each 200 kb
region of greatest difference between FSHD and control myoblasts is flanked by dashed, blue lines. Green arrows in panel C mark regions with
gender-dependent differences caused by X-chromosome inactivation. The two lower curves in these regions are from the two female-derived
myoblast samples and the other curves are myoblasts from males.
doi:10.1371/journal.pone.0027413.g005
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and embryonic fibroblast lines [26]. The second closest relation-
ship in replication timing was seen for myoblasts and ESC-derived
mesoderm cells, suggesting a common developmental origin. Since
the profiled fibroblasts and myoblasts both underwent in vivo
differentiation prior to isolation whereas all other cell types
examined were differentiated in vitro from embryonic stem cells, it
is possible that this similarity is an artifact of cell culture methods.
Primary smooth muscle cells have been shown to dedifferentiate in
culture to take on a fibroblast-like phenotype [47], suggesting that
at least some muscle types are at a differentiation state highly
similar to that of fibroblasts and demonstrating that culture
methods can influence the differentiation state. Further compli-
cating matters, fibroblast cell strains are also known to comprise a
variety of cell phenotypes [48,49]. Thus, more precise fibroblast
classification methods and timing profiles from other primary cell
types are needed to discern whether the observed similarity
between myoblast and fibroblast timing profiles is due to common
developmental origins or artifacts of in vitro culture and
differentiation.
Conclusions
In summary, we report the first genome-wide replication timing
study in primary human cultures. The lack of differences between
control and FSHD myoblasts in their DNA replication profiles
suggests that most major long-range chromatin organizational
events during myoblast formation proceed normally in FSHD
patients. Our findings also underscore the cell type-specificity and
reproducibility of genome-wide replication timing profiles in the
FSHD disease background between polymorphic primary cell lines
of the same cell type. Moreover, we found that human cells display
the same high similarity between myoblast and fibroblast genome-
wide replication timing profiles that was observed in mice.
Materials and Methods
Ethics Statement
This research was reviewed and approved by a Florida State
University Human Subjects Committee based on Institutional
Review Board approval at the Tulane Health Science Center and
the University of Rochester School of Medicine and Dentistry and
the University of Mississippi Medical Center in Jackson where
duly signed patient consent forms were obtained and actual
sample collection was performed.
Myoblast isolation and cell culture
Myoblasts cultures (Table 1) were generated from muscle
biopsies from three normal-controls, CM1 (42 Y, M), CM4 (27 Y,
M), and CM5 (31 Y, M), and four FSHD patients, FM1 (41 Y, M),
FM01 (45 Y, F), FM5 (29 Y, M), and FM7 (18 Y, F). The muscle
samples used for generating myoblast cultures were quadriceps
except for FM7 and CM5, which were from deltoid muscle and an
unknown surgical sample, respectively. The FSHD biopsies were
all from moderately affected tissue. FSHD samples had 3 (FM5
and FM7) or 6 (FM1 and FM01) copies of the D4Z4 repeat unit in
the contracted, pathogenic D4Z4 array at 4q35. D4Z4 array sizes
at 10q26 were known for three samples as follows; FM01 had one
contracted array with 7 copies of the D4Z4 repeat unit in addition
Figure 6. The region containing DXZ4 replicates early on the inactive X chromosome. Primary human myoblast replication timing profiles
are shown for 2 female (green) and 5 male (blue) individuals across the DXZ4 locus on chromosome X. Profiles for male lymphoblastoid (pink) and
female fetal lung fibroblast (black) cell lines are also shown. Gaps in each profile represent regions between microarray probes. The purple box on the
x-axis marks the position of DXZ4.
doi:10.1371/journal.pone.0027413.g006
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arrays with more than 15 copies. Myoblasts were propagated as
previously described [2,18]. The myoblast cultures at passage 9
used for this study contained .85% myoblasts as determined by
desmin immunostaining.
Lymphoblast [male lymphoblastoid cell line with normal (46,
XY) karyotype, CO202 ECCAC no. 94060845], ESC (BG01,
BG02, H7, H9), BG01-derived NPC, and ESC-derived mesendo-
derm, mesoderm, and definitive endoderm replication timing
datasets were previously published [27,39]. Unpublished fibroblast
[female fetal lung, IMR90 (T. Chandra et al., unpublished)] is
included with permission. Differentiation of BG02 ESCs to
mesendoderm (DE2) and definitive endoderm (DE4) was per-
formed by switching from defined media [50] to DMEM/F12
supplemented with 100 ng/ml Activin A and 20 ng/ml Fgf2 for
two and four days, respectively, with 25 ng/ml Wnt3a added on
the first day. Mesoderm was derived by adding 100 ng/ml BMP4
to DE2 cells.
Genome-wide replication timing profile generation
Genome-wide replication timing profiles from passage 9
myoblasts were generated and analyzed as described [23,35]
using a Human whole-genome triplex microarray with one probe
every 2.5 kb (Roche NimbleGen Inc., 090210_HG18_WG_
CGH_v3.1_HX3; 719,690 oligonucleotide probes). Sample label-
ing, microarray hybridization and data extraction were performed
according to standard procedures recommended by NimbleGen.
A complete replication-timing dataset for all probes is download-
able and graphically displayed at http://www.replicationdomain.
org [51]. In compliance with MIAME guidelines, all microarray
data has also been deposited in the GEO database (Accession
numbers pending manuscript acceptance).
Replication timing profile analysis
Replication timing datasets (Table S1) were normalized and
scaled together using the limma package in R as previously
described [23,35]. Loess smoothing was applied across a span of
300kb to normalized replication timing ratios (log2early/late) at
each probe to generate a genome-wide profile. For clustering and
identification of differentially replicated segments, timing values
were averaged in windows of approximately 200kb. Regions with
consistent changes in replication timing in FSHD myoblasts were
identified using a Monte Carlo algorithm [39] and custom R/
Bioconductor scripts.
Supporting Information
Table S1 Standard deviations, means and medians are
listed for all replication timing profile datasets (Sample
ID) used in this study.
(DOC)
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